WallStSmart
TXG

10X Genomics Inc

NASDAQ: TXG · HEALTHCARE · HEALTH INFORMATION SERVICES

$22.05
+9.16% today

Updated 2026-04-30

Market cap
$2.61B
P/E ratio
P/S ratio
4.05x
EPS (TTM)
$-0.35
Dividend yield
52W range
$8 – $26
Volume
2.4M

10X Genomics Inc (TXG) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
7 of 8
Last 8 quarters
Avg EPS surprise
+107.7%
Last 4 quarters
Revenue YoY growth
+0.6%
Most recent quarter
EPS YoY growth
+150.4%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-4.5%
Last 3 reports
Positive reaction rate
0%
0 of 3 quarters
Largest single-day move
-5.4%
2026-02-12
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-02-12$0.07+132.5%$19.15$18.12-5.4%
2025-10-28$-0.02+67.4%$13.59$12.90-5.1%
2025-08-07$0.28+190.3%$12.66$12.29-2.9%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.22$0.07+132.5%$166.03M+0.6%
2025-09-30$-0.07$-0.02+67.4%$149.00M-1.7%
2025-06-30$-0.31$0.28+190.3%$172.91M+12.9%
2025-03-31$-0.47$-0.28+40.4%$154.88M+9.8%
2024-12-31$-0.11$-0.14-27.3%$165.02M-10.3%
2024-09-30$-0.26$-0.02+92.3%$151.65M-1.3%
2024-06-30$-0.48$-0.32+33.3%$153.10M+4.3%
2024-03-31$-0.50$-0.50+0.0%$141.01M
2023-12-31$-0.36$-0.41-13.9%$183.98M
2023-09-30$-0.46$-0.79-71.7%$153.64M
2023-06-30$-0.40$-0.53-32.5%$146.82M

Frequently asked questions

Has 10X Genomics Inc beaten earnings estimates?
10X Genomics Inc has beaten Wall Street EPS estimates in 7 of its last 8 quarterly reports, with an average EPS surprise of +107.7% over the last 4 quarters.
How does TXG stock react to earnings?
TXG stock has moved an average of -4.5% in the trading day following earnings over its last 3 reports, with positive reactions in 0% of those quarters.
What is 10X Genomics Inc's revenue growth rate?
10X Genomics Inc reported year-over-year revenue growth of +0.6% in its most recent quarter, with EPS growing +150.4% year-over-year.